NVision Imaging Technologies and Aarhus University have received a €5.4 million (40 million Danish kroner) grant from Innovation Fund Denmark to advance clinical translation of hyperpolarized MRI for liver cancer diagnostics.
The funding, awarded under Denmark’s Grand Solutions in Quantum Technologies program, supports the MIRAQLE project, which aims to develop an MRI platform capable of visualizing cancer metabolism by boosting the MRI signal of an imaging agent, the partners said.
The MIRAQLE project, which will span laboratory research through preclinical and clinical studies in hepatocellular carcinoma, builds on NVision's existing research collaborations at Memorial Sloan Kettering Cancer Center and the University of Cambridge Department of Radiology, with a dedicated focus on liver cancer.
NVision's quantum physics-based hyperpolarization technology, Polaris, is under development for integration into existing MRI infrastructure at hospitals, according to the partners. Scanning with Polaris does not use radiation, they added.
